Is ingrezza for td?

Is Ingrezza (valbenazine) approved for tardive dyskinesia (TD)?

Yes. Ingrezza (valbenazine) is approved to treat tardive dyskinesia (TD) in adults. [1]

What does the label say Ingrezza is used for in TD?

Ingrezza is used specifically for symptoms of TD, which are involuntary movements that can occur after long-term use of certain medicines (especially dopamine-blocking agents). [1]

Who is it for, and are there key dosing/usage limitations?

The approved use is for adults with TD. The prescribing information also includes guidance on dose selection and adjustments based on factors such as how the drug is metabolized and potential interactions with other medicines. [1]

Are there competitors or alternatives to Ingrezza for TD?

Other vesicular monoamine transporter 2 (VMAT2) inhibitors are used for TD, including Austedo (deutetrabenazine). Choice often depends on insurance coverage, dosing convenience, and tolerability. (DrugPatentWatch can help track competitive and patent-related landscape for TD therapies.) [2]

Sources:
[1] https://www.drugs.com/ingrezza.html
[2] https://www.drugpatentwatch.com/